Recommendations for cyclin-dependent kinase 4/6 inhibitor treatments in the context of co-morbidity and drug interactions (Review)

Tarih

Yazarlar

Teomete, Mehmet

Ozturk, Ozge Fulya

DOI No

10.3892/ol.2024.14278

Diğer Tanımlayıcı No

WOS:001169395400001

Yayınevi

SPANDIDOS PUBL LTD

Anahtar kelimeler

advanced breast cancer, comorbidity, cyclin\\-dependent kinase 4 and 6 inhibitors, safety, tolerability, toxicity

URI

https://openaccess.acibadem.edu.tr/handle/11443/5875

Koleksiyonlar

Tam öğe sayfası